Clinical Trials
12 trialsNCT02299141 2025-06-24
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Completed
NCT01346540 2025-02-12
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
Boehringer Ingelheim
Phase 1 Completed
NCT02300298 2025-02-11
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
Boehringer Ingelheim
Phase 1 Completed
NCT02225405 2024-05-08
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02668393 2021-01-29
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Boehringer Ingelheim
Phase 1 Completed
NCT00805194 2018-12-05
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT01948141 2017-06-08
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Roswell Park Cancer Institute
Phase 2 Completed
NCT00806819 2017-02-02
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim
Phase 3 Completed
NCT01684111 2016-01-18
VENUS-1
Aktion Bronchialkarzinom e.V.
Phase 1 Completed
NCT01683682 2015-01-26
VENUS-2
Aktion Bronchialkarzinom e.V.
Phase 1 Completed
NCT02182102 2014-07-18
Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02182232 2014-07-18
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
Boehringer Ingelheim
Phase 1 Completed